XPRO India Ltd Q1 FY27 Earnings Analysis

- Ras Al Khaimah (RAK) plant expected to start trial production by August-September 2026, with commercial production by Q3 FY27, targeting over 50% capacity utilization by FY27-FY28. - Two Indian lines expected to be in full production in FY27, aiming for at least 50% utilization on the new Barjora line with volume growth underway. - Efforts to move towards higher value-added and ultrathin dielectric films (2-5 microns) to diversify product mix and increase revenue contribution. - Volume in coex division declined from ~33,014 MT to ~31,335 MT in FY26; growth expected as new capacity utilization increases. - Management focuses on volume growth, margin enhancement, and onboarding new customers for new capacities. - Price increases expected due to polymer/raw material cost inflation, but sustainability depends on market stability.

- Ras Al Khaimah (RAK) plant expected to start trial production by August-September 2026, with commercial production likely by Q3 FY27. - Full capacity utilization anticipated for two Indian lines in FY27 and FY28; UAE line expected to reach over 50% capacity utilization in FY27-28. - EBITDA margins expected to improve with new capacity and higher value-added specialty films, although no specific margin forecast disclosed. - Volume in coex division declined from 33,014 tons to 31,335 tons in FY26 due to production slowdown; expected to pick up in FY27. - Pricing environment volatile due to raw material (polymer) cost increases and forex fluctuations; price increases expected to stabilize at decent levels, benefiting margins. - Continued focus on higher value specialty films including ultrathin (2-5 micron) films, aiming for gradual mix shift in product portfolio over next 2-3 years. - Management optimistic about sustained earnings growth driven by capacity additions, premium product mix, and expanding market share.

- The biggest single capex chunk in FY 2026-27 is the Ras Al Khaimah (RAK) plant, expected to be capitalized around mid-year. - Additional capex may be done for value-added bits at the Bajora plant. - Coex operations in Ranjangaon and Greater Noida will see modest, routine capex but no new lines to be capitalized in FY 2026-27. - The Barjora line has already been capitalized (approx. INR 240 crores). - The Ras Al Khaimah line is still work in progress and not yet capitalized. - Fresh equity of USD 9 million was infused into the UAE subsidiary for growth. - Supplier credit in the form of ECB has been used to finance the new line at Barjora, with repayments underway. - The company is exploring Production Linked Incentive (PLI) opportunities for future lines, not yet applied for.

- No outstanding long-term borrowings for existing operations. - The company has availed supplier credit in the nature of ECB (External Commercial Borrowing) for financing the new line at Barjora. - Repayments of the ECB have already commenced, with 3 instalments repaid so far. - Fresh equity of USD 9 million was raised for the UAE subsidiary from a significant UAE participant, fully received and used for growth. - INR 74.63 crores raised via preferential infusion and QIP are held in banks pending utilization for stated purposes. - No mention of any planned new fundraising through debt or equity in the near future. - Board approved dividend INR 2 per share, indicating confidence in financial position without immediate need for new fundraising.

- The company has customers who want far more material than current limited capacity allows. - Existing customers require more volumes than presently supplied, indicating strong order demand. - Sales from the second line at Barjora have started with some products under approval. - No specific quantitative order book or pending orders value was disclosed during the call. - Demand is progressively ramping up, but capacity constraints currently limit the full fulfillment. - New customer onboarding and applications are underway for the new capacity. - Management focuses on volume growth and margin enhancement amidst dynamic pricing. - No indication of order backlog delays; expansion lines are expected to meet growing demand in FY '27 and FY '28.